Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2016

View Archived Issues

First viable murine model of cblC type CMAH reported

Biallelic mutations in PPA2 are associated with mitochondrial dysfunction

Highland Therapeutics enters agreement for IBD drug candidate

Novel ciclosporin formulation PADciclo may allow lower doses for treating dry eye

Durable responses seen with oncolytic adenovirus CG-0070 in phase II/II bladder cancer trial

Australian institutions sign MOU to establish Australian Hepatitis C Elimination Program

Anti-sFlt-1 MAb preserves normal lung structure and prevents pulmonary hypertension in models of BPD

Merck & Co. receives positive opinion for Zepatier in the E.U.

Checkpoint Therapeutics signs BET inhibitor license agreements with Jubilant and TG Therapeutics

Humira receives CHMP positive opinion to treat certain forms of noninfectious uveitis

ConverGene patents inhibitors of bromodomain-containing proteins

H. Lundbeck discloses BACE1 inhibitors

FORGE Life Science develops antivirals

Romark Laboratories presents prodrugs of tizoxanide

FDA approves Zinbryta as once-monthly treatment for relapsing MS

Shanghai Shaletech Technology announces EGFR inhibitors

EMA begins review of guidelines governing first-in-human trials

European Commission approves Strimvelis for ADA-SCID

FDA grants accelerated approval to Ocaliva for primary biliary cholangitis

EMA's CHMP gives positive opinion on brentuximab vedotin for post-transplant Hodgkin's lymphoma

FDA approves Axumin to detect recurrent prostate cancer

EMA committee does not support approval of Ninlaro capsules

EMA committee recommends approval of Epclusa for hepatitis C

Saxagliptin/dapagliflozin receives positive opinion in E.U.

EMA committee hands down positive opinion to extend Kyprolis indication

FDA grants orphan drug designation to Portage's BHV-4157

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...